1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSupports early-stage testing of pharmacologic or neuromodulatory device-based interventions for mental disorders.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Universities, Nonprofits. Confirm the full requirements in the official notice before applying.
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required) is funded by NIH - National Institute of Mental Health. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs) is sponsored by Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) and Neuroendocrine Tumor Research Foundation (NETRF). This grant supports early-career basic or clinical scientists to conduct novel and innovative research in nuclear medicine related to neuroendocrine tumors, with the aim of generating preliminary data for further funding.
The Merck Stimulating Innovative Research Grant Program 2026 includes a dedicated grant topic for artificial intelligence in cell culture media and process development, offering up to EUR 150,000 per year for up to 3 years. The program accelerates innovation through collaborative research, early engagement with industry experts, and translation of novel ideas into practical solutions. In 2026, priority areas also include in-vitro models for neuroinflammatory diseases (EUR 250,000/year for 2 years) and innovative approaches to contaminated materials remediation (EUR 150,000/year for 2 years). The two-stage application process begins with non-confidential submissions, followed by deep-dive workshops where finalists collaborate with Merck scientists and managers to jointly optimize proposals. The AI-specific grant focuses on applying machine learning and AI to optimize cell culture media formulation, bioprocess parameter optimization, and manufacturing quality control.
The Health and Extreme Weather highlighted topic went live September 1, 2026 with eleven awarding institutes and expires May 1, 2028. There is no set-aside, no separate deadline, and no review criteria — which makes the institute-by-institute language the only real signal, and it is not uniform.
Read articleThe NOURISH Autoimmunity Digital Health Challenge runs three phases to August 2028: 10 winners at $20,000, then 5 at $30,000, then 3 at $100,000. It is a prize competition, not a grant — no indirect costs, no cost reimbursement, and a rule that quietly disqualifies the obvious applicant.
Read articlePMHCA (HRSA-26-058) makes $9.79 million available for up to 22 awards of up to $445,000 to build tele-consultation networks that help pediatric primary care providers manage children's behavioral health. The catch buried in the eligibility section: applicants must NOT already hold a PMHCA award — which effectively reserves the new-state lane for the eight unfunded states and territories, plus tribes everywhere. Here's how to read it and what wins.
Read article